|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GTF2IRD2B |
Gene summary for GTF2IRD2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GTF2IRD2B | Gene ID | 389524 |
| Gene name | GTF2I repeat domain containing 2B | |
| Gene Alias | GTF2IRD2 | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6EKJ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 389524 | GTF2IRD2B | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.24e-06 | 3.26e-01 | 0.0155 |
| 389524 | GTF2IRD2B | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.18e-04 | 4.12e-01 | -0.0811 |
| 389524 | GTF2IRD2B | HTA11_78_2000001011 | Human | Colorectum | AD | 3.19e-10 | 5.79e-01 | -0.1088 |
| 389524 | GTF2IRD2B | HTA11_347_2000001011 | Human | Colorectum | AD | 8.59e-20 | 6.69e-01 | -0.1954 |
| 389524 | GTF2IRD2B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.53e-09 | 5.32e-01 | -0.1207 |
| 389524 | GTF2IRD2B | HTA11_83_2000001011 | Human | Colorectum | SER | 2.97e-02 | 3.61e-01 | -0.1526 |
| 389524 | GTF2IRD2B | HTA11_696_2000001011 | Human | Colorectum | AD | 2.43e-14 | 6.73e-01 | -0.1464 |
| 389524 | GTF2IRD2B | HTA11_866_2000001011 | Human | Colorectum | AD | 2.98e-23 | 6.96e-01 | -0.1001 |
| 389524 | GTF2IRD2B | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.99e-16 | 6.98e-01 | -0.059 |
| 389524 | GTF2IRD2B | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.56e-02 | 3.68e-01 | -0.1706 |
| 389524 | GTF2IRD2B | HTA11_546_2000001011 | Human | Colorectum | AD | 1.35e-18 | 1.04e+00 | -0.0842 |
| 389524 | GTF2IRD2B | HTA11_9341_2000001011 | Human | Colorectum | SER | 4.31e-02 | 4.35e-01 | -0.00410000000000005 |
| 389524 | GTF2IRD2B | HTA11_866_3004761011 | Human | Colorectum | AD | 2.63e-06 | 3.43e-01 | 0.096 |
| 389524 | GTF2IRD2B | HTA11_4255_2000001011 | Human | Colorectum | SER | 5.11e-06 | 6.38e-01 | 0.0446 |
| 389524 | GTF2IRD2B | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.17e-02 | 5.79e-01 | 0.0131 |
| 389524 | GTF2IRD2B | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.51e-03 | 5.04e-01 | -0.0177 |
| 389524 | GTF2IRD2B | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.27e-11 | 6.32e-01 | 0.0338 |
| 389524 | GTF2IRD2B | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.78e-11 | 4.95e-01 | 0.0674 |
| 389524 | GTF2IRD2B | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.19e-11 | 8.88e-01 | 0.0112 |
| 389524 | GTF2IRD2B | HTA11_11156_2000001011 | Human | Colorectum | AD | 1.04e-04 | 9.09e-01 | 0.0397 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.1489N>G | p.Leu497Val | p.L497V | Q6EKJ0 | protein_coding | deleterious(0.04) | probably_damaging(0.952) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2537N>C | p.Glu846Ala | p.E846A | Q6EKJ0 | protein_coding | tolerated(0.1) | probably_damaging(0.956) | TCGA-C8-A12L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GTF2IRD2B | SNV | Missense_Mutation | c.1989N>C | p.Gln663His | p.Q663H | Q6EKJ0 | protein_coding | tolerated(0.07) | probably_damaging(0.969) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2638N>G | p.Thr880Ala | p.T880A | Q6EKJ0 | protein_coding | tolerated(0.83) | benign(0) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2260N>T | p.Ala754Ser | p.A754S | Q6EKJ0 | protein_coding | tolerated(0.06) | probably_damaging(0.968) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.439G>T | p.Gly147Trp | p.G147W | Q6EKJ0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| GTF2IRD2B | SNV | Missense_Mutation | c.1872N>C | p.Met624Ile | p.M624I | Q6EKJ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.775) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2272N>A | p.Asp758Asn | p.D758N | Q6EKJ0 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2590G>A | p.Glu864Lys | p.E864K | Q6EKJ0 | protein_coding | tolerated(0.21) | benign(0.017) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GTF2IRD2B | SNV | Missense_Mutation | novel | c.2126C>T | p.Thr709Met | p.T709M | Q6EKJ0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-VS-A8Q9-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |